BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Armistice Capital lost almost 19% last month, the biggest decline for the hedge fund’s flagship money pool since its launch ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...

Diagnostica Stago, Inc., a global leader in hemostasis and thrombosis diagnostics, is pleased to announce a special educational webinar, "The Importance of Routine Coagulation Testing," in recognition ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting ...

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

Scotiabank analyst Greg Harrison maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) today and set a price target of ...

Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at ...

Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and ...

Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a buyout and high-dose Ocrevus missed a study goal.